Novartis says Cosentyx could be used as an early intervention in psoriasis after new data suggests it is the first drug of its kind to modify the course of the disease. The Swiss big pharma ...

Beating AbbVie’s TNF blocker Humira in a head-to-head trial has become a rite of passage for new interleukin-targeting drugs in the immunology market, but Novartis’ Cosentyx has just fallen ...